Cover Image

Chronic widespread pain in spondyloarthritis

F. Atzeni, L. Boccassini, M. Di Franco, A. Alciati, A. Marsico, M. Cazzola, G. Cassisi, P. Sarzi-Puttini
  • L. Boccassini
    Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
  • M. Di Franco
    Rheumatology Unit, Department of Internal Medicine and Medical Specialties, La Sapienza University, Rome, Italy
  • A. Alciati
    Hermanas Hospitalarias, FoRiPsi, Department of Clinic Neurosciences, Villa San Benedetto Menni, Albese con Cassano (CO), Italy
  • A. Marsico
    Reumatology Unit, S.S. Annunziata Hospital, Taranto, Italy
  • M. Cazzola
    Rehabilitation Unit, Busto Arsizio Ospedale di Circolo, Presidio Ospedaliero di Saronno (VA), Italy
  • G. Cassisi
    Rheumatology Branch, Specialist Outpatients Department, Belluno, Italy
  • P. Sarzi-Puttini
    Rheumatology Unit, L. Sacco University Hospital, Milan, Italy


The pain associated with spondyloarthritis (SpA) can be intense, persistent and disabling. It frequently has a multifactorial, simultaneously central and peripheral origin, and may be due to currently active inflammation, or joint damage and tissue destruction arising from a previous inflammatory condition. Inflammatory pain symptoms can be reduced by non-steroidal anti-inflammatory drugs, but many patients continue to experience moderate pain due to alterations in the mechanisms that regulate central pain, as in the case of the chronic widespread pain (CWP) that characterises fibromyalgia (FM). The importance of distinguishing SpA and FM is underlined by the fact that SpA is currently treated with costly drugs such as tumour necrosis factor (TNF) inhibitors, and direct costs are higher in patients with concomitant CWP or FM than in those with FM or SpA alone. Optimal treatment needs to take into account symptoms such as fatigue, mood, sleep, and the overall quality of life, and is based on the use of tricyclic antidepressants or selective serotonin reuptake inhibitors such as fluoxetine, rather than adjustments in the dose of anti-TNF agents or disease-modifying drugs.


Spondyloarthritis, Fibromyalgia, Prevalence, Disease activity, Ankylosing spondylitis disease activity score, Bath ankylosing spondylitis disease activity index.

Full Text:

Submitted: 2014-06-06 17:46:57
Published: 2014-06-06 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Copyright (c) 2014 F. Atzeni, L. Boccassini, M. Di Franco, A. Alciati, A. Marsico, M. Cazzola, G. Cassisi, P. Sarzi-Puttini

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
© PAGEPress 2008-2018     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185